<
Von Version < 15.1 >
bearbeitet von Thomas Brinkmeier
am 2023/06/20 21:47
Auf Version < 9.1 >
bearbeitet von Thomas Brinkmeier
am 2021/01/05 22:05
>
Änderungskommentar: Es gibt keinen Kommentar für diese Version

Zusammenfassung

Details

Wikiderm.EntryClass[0]
Eintrag
... ... @@ -65,50 +65,11 @@
65 65  (% class="Feature" %)Bsp:(%%) Mycoplasma pneumoniae, HIV
66 66  
67 67  (% class="Eintrag-2" %)
68 -(% class="Feature" %)DD:(%%) (% class="Bullet" %)-(%%) (% class="Abbreviation" %)AGEP(%%)
68 +(% class="Feature" %)DD:(%%) (% class="Abbreviation" %)AGEP(%%), Dermatitis herpetiformis, eosinophile pustulöse Follikulitis Ofuji, Impetigo contagiosa, Pemphigus foliaceus, Psoriasis pustulosa
69 69  
70 -(% class="Ebene-1" %)
71 -(% class="Bullet" %)-(%%) Dermatitis herpetiformis
72 -
73 -(% class="Ebene-1" %)
74 -(% class="Bullet" %)-(%%) eosinophile pustulöse Follikulitis Ofuji
75 -
76 -(% class="Ebene-1" %)
77 -(% class="Bullet" %)-(%%) Impetigo contagiosa
78 -
79 -(% class="Ebene-1" %)
80 -(% class="Bullet" %)-(%%) Pemphigus foliaceus
81 -
82 -(% class="Ebene-1" %)
83 -(% class="Bullet" %)-(%%) anuläre Psoriasis pustulosa
84 -
85 -(% class="Ebene-2" %)
86 -(% class="Feature" %)Bsp:(%%) annular pustular psoriasis
87 -
88 -(% class="Ebene-2" %)
89 -(% class="Feature" %)Lit:(%%) Pediatr Dermatol. 2023 Jan 31. [[http:~~/~~/doi.org/10.1111/pde.15251>>url:http://doi.org/10.1111/pde.15251]]
90 -
91 -(% class="Ebene-1" %)
92 -(% class="Bullet" %)-(%%) Tinea incognito
93 -
94 -(% class="Ebene-2" %)
95 -(% class="Feature" %)Lit:(%%) [[Kalkan, G., Demirseren, D. D, Güney, C. A, & Aktaş, A. (2020). A case of tinea incognito mimicking subcorneal pustular dermatosis. Dermatology Online Journal, 26(2)>>url:https://escholarship.org/uc/item/46g9x55w]]
96 -
97 97  (% class="Eintrag-2" %)
98 -(% class="Feature" %)Lit:(%%) (% class="Bullet" %)-(%%) {{pdfbox Datei="Varia, Pustulosis subcornealis Sneddon-Wilkinson, Arch Inflamm, 2016.pdf" /}}
71 +(% class="Feature" %)Lit:(%%) {{pdfbox Datei="Varia, Pustulosis subcornealis Sneddon-Wilkinson, Arch Inflamm, 2016.pdf" /}}
99 99  
100 -(% class="Ebene-1" %)
101 -(% class="Bullet" %)-(%%) Open Access Maced J Med Sci. 2020 Jun 05; 8(T1):12-15. [[https:~~/~~/doi.org/10.3889/oamjms.2020.4870>>url:https://doi.org/10.3889/oamjms.2020.4870]]
102 -
103 -(% class="Ebene-1" %)
104 -(% class="Bullet" %)-(%%) International Journal of Women's Dermatology, Volume 6, Issue 3, 2020, Pages 131-136, ISSN 2352-6475, [[https:~~/~~/doi.org/10.1016/j.ijwd.2020.02.003>>url:https://doi.org/10.1016/j.ijwd.2020.02.003]]
105 -
106 -(% class="Ebene-1" %)
107 -(% class="Bullet" %)-(%%) SAGE Open Med Case Rep. 2019 Jan 30;7:2050313X19826432. [[http:~~/~~/doi.org/10.1177/2050313X19826432>>url:http://doi.org/10.1177/2050313X19826432]]
108 -
109 -(% class="Ebene-1" %)
110 -(% class="Bullet" %)-(%%) JAAD Case Rep. 2022 Jan 21;21:185-188. [[http:~~/~~/doi.org/10.1016/j.jdcr.2021.04.039>>url:http://doi.org/10.1016/j.jdcr.2021.04.039]]
111 -
112 112  (% class="Eintrag-2" %)
113 113  (% class="Feature" %)Th:(%%) (% class="Bullet" %)-(%%) lokal
114 114  
... ... @@ -116,12 +116,6 @@
116 116  (% class="Bullet" %)-(%%) Farbstoffe (**[[Antiseptika]]**)
117 117  
118 118  (% class="Ebene-2" %)
119 -(% class="Bullet" %)-(%%) Mometasonfuroat
120 -
121 -(% class="Ebene-3" %)
122 -(% class="Feature" %)Lit:(%%) Dermatol Ther. 2021 Nov 27:e15235. [[http:~~/~~/doi.org/10.1111/dth.15235>>url:http://doi.org/10.1111/dth.15235]]
123 -
124 -(% class="Ebene-2" %)
125 125  (% class="Bullet" %)-(%%) Tacalcitol
126 126  
127 127  (% class="Ebene-3" %)
... ... @@ -200,8 +200,14 @@
200 200  (% class="Feature" %)Stoff:(%%) (% class="Bullet" %)-(%%) **[[Infliximab]]**
201 201  
202 202  (% class="Ebene-4" %)
203 -(% class="Feature" %)Lit:(%%) Arch Dermatol 2001; 137: 1571-4, Dermatol Ther. 2022 May 4:e15552. [[http:~~/~~/doi.org/10.1111/dth.15552>>url:http://doi.org/10.1111/dth.15552]]
158 +(% class="Feature" %)Phar:(%%) Remicade^^®^^
204 204  
160 +(% class="Ebene-4" %)
161 +(% class="Feature" %)Dos:(%%) 5 mg/kg i.v.
162 +
163 +(% class="Ebene-4" %)
164 +(% class="Feature" %)Lit:(%%) Arch Dermatol 2001; 137: 1571-4
165 +
205 205  (% class="Ebene-3" %)
206 206  (% class="Bullet" %)-(%%) Adalimumab
207 207  
... ... @@ -209,11 +209,4 @@
209 209  (% class="Feature" %)Lit:(%%) Ann Dermatol Venereol. 2013 Dec;140(12):797-800 (Frankreich)
210 210  
211 211  (% class="Ebene-5" %)
212 -(% class="Feature" %)PT:(%%) (% class="Abbreviation" %)CR(%%)
213 -
214 -(% class="Ebene-2" %)
215 -(% class="Bullet" %)-(%%) Guselkumab
216 -
217 -(% class="Ebene-3" %)
218 -(% class="Feature" %)Lit:(%%) Int J Dermatol. 2021 Apr;60(4):e153-e154. [[http:~~/~~/doi.org/10.1111/ijd.15311>>url:http://doi.org/10.1111/ijd.15311]]
219 -
173 +(% class="Feature" %)PT:(%%) CR

Artikelinhalt

©WIKIDERM GmbH • KontaktFAQImpressumNutzungsbedingungenDatenschutzerklärungFacebook